MarketTwits
⚡️💥🇪🇺🇺🇸#REGN #RO #коктейли RTRS: Европа скоро одобрит антиковидный коктейль от Regeneron-Roche EU DRUGS REGULATOR SOON TO APPROVE USE OF REGENERON-ROCHE AND CELLTRION MONOCLONAL ANTIBODY TREATMENTS AGAINST COVID-19 - SOURCES
💥🇨🇭#RO #REGN #препараты #ковид
Швейцария одобрила антиковидный препарат Ronapreve от Roche и Regeneron
Швейцария одобрила антиковидный препарат Ronapreve от Roche и Regeneron
🇨🇭#RO #отчетность
Roche FY 21 Earnings:
- Revenue: CHF62.8B (exp CHF62.33B)
- Core EPS: CHF19.81 (exp CHF20.40)
- Sales Expected Stable Or Grow In Low-Single Digits
Roche FY 21 Earnings:
- Revenue: CHF62.8B (exp CHF62.33B)
- Core EPS: CHF19.81 (exp CHF20.40)
- Sales Expected Stable Or Grow In Low-Single Digits
🇨🇭#RO #отчетность
Roche
Q1 Group sales = +11% to CHF16.45B
Pharmaceuticals Division sales = +6% to CHF11.2B
Ronapreve (REGEN-COV) sales = +272% to CHF 587M.
Roche
Q1 Group sales = +11% to CHF16.45B
Pharmaceuticals Division sales = +6% to CHF11.2B
Ronapreve (REGEN-COV) sales = +272% to CHF 587M.
⚡️🇪🇺#RO #отчетность
Roche H1 22 Earnings
- H1 Core EPS CHF 11.76 (est CHF 11.05)
- H1 Revenue CHF 32.03B (est CHF 31.89B)
- Confirms FY 22 Outlook
Roche H1 22 Earnings
- H1 Core EPS CHF 11.76 (est CHF 11.05)
- H1 Revenue CHF 32.03B (est CHF 31.89B)
- Confirms FY 22 Outlook